Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.
PURPOSE:Genetically-targeted therapies are both promising and costly advances in the field of oncology.Several treatments for metastatic melanoma with a mutation in the BRAF gene have been approved.They extend life but are more expensive than the previous standard of care (dacarbazine).Vemurafenib, the first drug in this class, costs $13,000 per mo